KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBT Margin (2016 - 2026)

Boston Scientific's EBT Margin history spans 18 years, with the latest figure at 22.33% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 507.0% to 22.33% in Q1 2026 year-over-year; TTM through Mar 2026 was 18.15%, a 403.0% increase, with the full-year FY2025 number at 16.86%, up 324.0% from a year prior.
  • EBT Margin hit 22.33% in Q1 2026 for Boston Scientific, up from 13.24% in the prior quarter.
  • Over the last five years, EBT Margin for BSX hit a ceiling of 22.33% in Q1 2026 and a floor of 5.16% in Q1 2022.
  • Historically, EBT Margin has averaged 13.89% across 5 years, with a median of 13.24% in 2025.
  • Biggest five-year swings in EBT Margin: plummeted -874bps in 2022 and later skyrocketed 957bps in 2023.
  • Tracing BSX's EBT Margin over 5 years: stood at 12.21% in 2022, then rose by 11bps to 13.56% in 2023, then dropped by -5bps to 12.83% in 2024, then rose by 3bps to 13.24% in 2025, then surged by 69bps to 22.33% in 2026.
  • Business Quant data shows EBT Margin for BSX at 22.33% in Q1 2026, 13.24% in Q4 2025, and 18.54% in Q3 2025.